Australia’s Pharmaceutical Benefit Advisory Committee (PBAC) has recommended ‘a-flagging’, or marking as equivalent and substitutable at the point of dispensing, two biosimilars of Humira (adalimumab) and one of Lantus (insulin glargine).
Australia’s Pharmaceutical Benefit Advisory Committee (PBAC) has recommended ‘a-flagging’, or marking as equivalent and substitutable at the point of dispensing, two biosimilars of Humira (adalimumab) and one of Lantus (insulin glargine).
Following the PBAC’s July 2018 meeting, the report of which has just been published, Amgen’s Amgevita (adalimumab) and Merck Sharp...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
